Organisation paid for research Program year 2025 Source: CMS Open Payments

Boster Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$1,120,140

75 payments

Through program year 2025, Boster Research Center LLC is reported as receiving $1,120,140 in research payments, across 75 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $485,956 42
2024 Research $399,831 23
2023 Research $234,352 10

Breakdown

Who paid Research payments · program years 2023–2025
  1. Genzyme Corporation $1,116,870 74 payments
  2. Hoffmann-La Roche Limited $3,270 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis $302,148 30 payments
  2. A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $231,199 7 payments
  3. A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $218,578 5 payments
  4. An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis $199,097 8 payments
  5. A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) $129,775 20 payments
  6. A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $36,073 4 payments
  7. PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $3,270 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record